Back to top
more

DIADEXUS INC (DDXS)

(Delayed Data from OTC)

$0.01 USD

0.01
67,488

-0.01 (-35.00%)

Updated Jun 21, 2016 02:15 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

diaDexus Inc. [DDXS]

Reports for Purchase

Showing records 21 - 40 ( 40 total )

Company: diaDexus Inc.

Industry: Medical - Products

Record: 21

03/06/2014

Company Report

Pages: 4

Reported 4Q13 and full year results

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 10.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 22

03/06/2014

Company Report

Pages: 11

Q4 slightly ahead, 3 new tests licensed from TMO, reiterate STRONG BUY

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 23

11/12/2013

Company Report

Pages: 8

Darapladib study fails to meet primary endpoint, DDXS selloff overdone, reiterate SB

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 24

11/12/2013

Company Report

Pages: 12

Results from GSK trial disappoint but outlook for business remains unchanged.

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 25

11/06/2013

Company Report

Pages: 12

Research Update: DDXS: And the revenues growth keeps going and going

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 26

10/30/2013

Company Report

Pages: 8

Q3 2013 results beat, reiterating STRONG BUY, raising PT to $2.90

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 27

10/16/2013

Company Report

Pages: 7

PLAC Activity test clinical program advances after FDA meeting

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 28

09/13/2013

Company Report

Pages: 10

Notes from the road - company HQ visit and non-deal road show - raise PT to $2.15

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 29

08/19/2013

Company Report

Pages: 12

Q2FY13 results above expectations as physicians become aware of PLAC test benefits

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 30

08/19/2013

Company Report

Pages: 12

Q2FY13 results above expectations

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 31

08/09/2013

Company Report

Pages: 7

Q2 2013 results heartening, reiterating STRONG BUY, raising PT to $1.80

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 32

07/25/2013

Company Report

Pages: 15

Initiating with a STRONG BUY, $1.50PT

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 50.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 33

07/23/2013

Company Report

Pages: 2

We are transferring coverage as a result of reorganization of our coverage universe

Provider: STONEGATE CAPITAL MARKETS

Price: 10.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 34

07/22/2013

Company Report

Pages: 3

Update - 1Q13

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 10.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 35

05/13/2013

Industry Report

Pages: 12

Revenues remain steady as Company expands its reimbursement footprint

Provider: STONEGATE CAPITAL MARKETS

Analyst: RODRIGUEZ M

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 36

04/19/2013

Company Report

Pages: 14

Initiate coverage with a price target of $0.85

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 50.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 37

11/15/2012

Company Report

Pages: 12

Results in line with expectations while opportunity arises in the Czech Republic

Provider: STONEGATE CAPITAL MARKETS

Analyst: RODRIGUEZ M

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 38

10/08/2012

Company Report

Pages: 2

We are transferring coverage of DDXS to Marco Rodriguez as the previous analyst is no longer with the firm

Provider: STONEGATE CAPITAL MARKETS

Price: 10.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 39

08/15/2012

Company Report

Pages: 10

Research Update: DDXS: While Revenues Are In line, Economies of Scale Improve Bottom Line

Provider: STONEGATE CAPITAL MARKETS

Analyst: ENGEL L

Price: 25.00

Research Provided by a Third Party

Company: diaDexus Inc.

Industry: Medical - Products

Record: 40

05/14/2012

Company Report

Pages: 20

Initiation of Coverage: DDXS: Uncovering Your Hidden Risks for Coronary Heart Disease and Stroke

Provider: STONEGATE CAPITAL MARKETS

Analyst: ENGEL L

Price: 50.00

Research Provided by a Third Party
// eof